Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

ï»¿Targeted Focal Therapy Emerges as Alternative to Active Surveillance or Definitive Treatment

May 25th 2012

Focal therapy offers some men with localized prostate cancer a solution between active surveillance and definitive treatment with surgery and/or radiation.

Dr. Sieber on Managing Bone Health After ADT

May 25th 2012

Dr. Paul Sieber, from the Urological Association of Lancaster, on Managing Bone Health After the Introduction of ADT.

Prostate Cancer Screening: A Q&A With Oliver Sartor, MD, and Leonard G. Gomella, MD

May 24th 2012

Oliver Sartor, MD, and Leonard G. Gomella, MD, discuss multiple topics involved with prostate-specific antigen (PSA) screening, including PSA velocity, guidelines, and cutoff age.

NCCN 17th Annual Conference: Clinical Practice Guidelines & Quality Cancer Care

May 23rd 2012

At this year's annual NCCN conference, the organization presented updates in 13 areas, including specific disease states and general screening methods.

Federal Panel Rejects Routine Prostate Cancer Screening

May 22nd 2012

The USPSTF has made a final recommendation against routine screening for prostate cancer in asymptomatic males through PSA testing.

Dr. Gomella on the Impact of the New USPSTF PSA Rating

May 22nd 2012

Dr. Leonard Gomella, form the Jefferson Kimmel Cancer Center, on the Impact of the New USPSTF PSA Rating.

Dr. Oliver Sartor Discusses PSA Screening

May 22nd 2012

Dr. Oliver Sartor, from Tulane Cancer Center, Discusses Prostate-Specific Antigen (PSA) Screening

Dr. Gomella Discusses the IMPACT Trial Survival Benefit

May 21st 2012

Dr. Leonard Gomella, from the Jefferson Kimmel Cancer Center, on the Provenge IMPACT Trial Survival Benefit

Politics and Science Intersect in PSA Screening

May 21st 2012

Leonard G. Gomella, MD, discusses the public policy and medical implications of the US Preventive Services Task Force's draft recommendation on PSA screening.

UK Advisory Group Reverses Decision on Abiraterone; Drug Expected to Be Funded

May 18th 2012

The prostate cancer drug abiraterone acetate is expected be provided for patients through England's publicly funded healthcare system after NICE reversed its initial recommendation.

Dr. Goy on Neoadjuvant Hormonal Therapy Plus Zytiga

May 18th 2012

Dr. Andrew Goy, from John Theurer Cancer Center, on Neoadjuvant Hormonal Therapy Plus Zytiga

Neoadjuvant Zytiga Helps Eliminate Some Patients' Prostate Tumors

May 16th 2012

Combined neoadjuvant treatment with abiraterone acetate (Zytiga) plus standard hormonal therapy before prostatectomy eradicated or nearly eradicated tumors in 34% of patients with localized high-risk prostate cancer.

Dr. Gomella on Neoadjuvant Hormonal Therapy Plus Zytiga

May 16th 2012

Dr. Leonard Gomella, from Jefferson Kimmel Cancer Center, on Neoadjuvant Hormonal Therapy Combined With Abiraterone Acetate

New Therapies for Prostate Cancer: The Practicalities

May 15th 2012

Now, with four new agents approved in the last two years and two promising agents in the pipeline, therapy selection and potential outcomes are changing.

5-alpha Reductase Inhibitors Help Prostate Cancer Patients on Active Surveillance

May 14th 2012

Men with low-risk prostate cancer who have opted for active surveillance are about half as likely to experience pathologic progression or abandon active surveillance if they take a 5-ARI.

Sipuleucel-T Stimulates Response in Localized Setting, Study Finds

May 11th 2012

The neoadjuvant administration of sipuleucel-T may stimulate an immune response in patients with localized prostate cancer without adversely affecting their surgeries.

Dr. Dreicer on Utilizing New Prostate Cancer Therapies

May 9th 2012

Dr. Robert Dreicer, from the Cleveland Clinic, on Utilizing New Prostate Cancer Therapies

Dutasteride May Slow Prostate Cancer Progression

May 5th 2012

Dutasteride may postpone disease progression in men with low-risk prostate cancer who have opted for an active surveillance strategy.

Talking to Prostate Cancer Patients About Sipuleucel-T: Nurses Assure Smooth Sailing During Treatment

May 4th 2012

Nurses play vital roles in assuring that patients with metastatic castration-resistant prostate cancer (mCRPC) are optimally treated with sipuleucel-T.

Dr. Leonard Gomella Discusses PSA Velocity

May 1st 2012

Dr. Leonard Gomella, from Jefferson Kimmel Cancer Center, Discusses PSA Velocity